Abstract-Intracerebral hemorrhage (ICH) is an often fatal type of stroke that kills Ϸ30 000 people annually in the United
D
uring intracerebral hemorrhage (ICH), rapid accumulation of blood within brain parenchyma leads to disruption of normal anatomy and increased local pressure. Depending on the dynamic of hematoma expansion (growth), the primary damage occurs within minutes to hours from the onset of bleeding and is primarily the result of mechanical damage associated with the mass effect. 1 Secondary damage is, for the most part, attributable to the presence of intraparenchymal blood and may be dependent on the initial hematoma volume, age, or ventricular volume. 1 It may occur through many parallel pathological pathways, including: (1) cytotoxicity of blood; 2, 3 (2) hypermetabolism; 4 (3) excitotoxicity; 5 (4) spreading depression; 6 and (5) oxidative stress and inflammation. 3, [7] [8] [9] [10] [11] [12] [13] Ultimately, this pathogenesis leads to irreversible disruption of the components of the neurovascular unit, constituting gray and white matter, and is followed by blood-brain barrier disruption and deadly brain edema with massive brain cell death. 2,3,5,7,14 -16 Whereas inflammatory mediators generated locally in response to brain death/ injury have the capacity to augment damage caused by ICH (secondary injury), the involvement of inflammatory cells, eg, microglia/macrophages, is vital for removal/cleanup of cellular debris from hematoma, the source of ongoing inflammation. 17 The timely removal of damaged tissue is essential for reducing the length of deleterious pathological process and thereby allowing for faster and more efficient recovery.
Blood Cytotoxicity and Oxidative Stress as Mediators of Cell Death After ICH
After ICH, the extravasated blood components (primarily erythrocytes and plasma proteins) and the damage-associated molecular patterns, including nucleic acids, extracellular matrix components, proteins, lipid mediators, ATP, and uric acid released from necrotic and damaged tissue, impose a strong cytotoxic, pro-oxidative, and proinflammatory insult toward adjacent viable brain cells and could be seen as early as minutes after onset of ICH. At this early stage, the toxicity of extravasated blood plasma components including bloodderived coagulation factors, complement components, immunoglobulins, and other bioactive molecules are proposed to act as contributors to ICH-affected tissue damage. [2] [3] 11 Subsequently, red blood cell lysis starts at Ϸ24 hours and continues for the next several days, leading to release of cytotoxic hemoglobin (Hb) with further deterioration of the pathological status quo. 2 Hb and its degradation products, heme and iron, directly compromise the well-being of neighboring brain cells. 2,18 -20 Hb and heme are potent cytotoxic chemicals capable of causing death to many brain cells. Prominently, the mechanism of Hb toxicity is via generating free radicals (mainly through Fenton-type mechanism) and massive oxidative damage to proteins, nucleic acids, carbohydrates, and lipids. 2, 18, 21, 22 Therefore, finding means of controlling hemolysis, and detoxification, and absorption of Hb, heme, and iron ( Figure 1 ) may have important clinical implications. We review the role of selected pathways involved in blood detoxification process, including transcriptional regulation of selected molecules with a role in hematoma clearance. to a lesser extent by lungs, kidneys, skin, and adipose tissue. 20, 23 Hp is a heteromeric enzyme composed of alpha and beta chains. The primary function of Hp in blood is to bind and neutralize nephrotoxic free Hb in case of intravascular hemolysis. 23 Hp-Hb complexes are consequently removed from the circulation by a specialized subclass of macrophages expressing CD163, a scavenger receptor and a member of the group B scavenger receptor cysteine-rich superfamily. 23 Under normal circumstances, Hp represents an effective mechanism by which our body is protected from Hb toxicity. However, because Hp synthesis is not increased by low Hp levels and Hp is not recycled by macrophages, it may take 5 to 7 days for the Hp level to recover if completely sequestered by Hb. Thus, massive hemolysis may lead to persistent hypohaptoglobinemia. Interestingly, we have recently demonstrated that Hp is also produced locally in rat brain after ICH and its expression is significantly increased around the hematoma within hours from the onset of ICH. 20 The brain-derived Hp appeared to be synthesized and released by oligodendrocytes. Because oligodendroglia are abundant in white matter and are present throughout the gray matter, local production of Hp by these cells likely represents an important endogenous mechanism protecting brain against the extravascular Hb toxicity. Indirect support for such a claim includes (1) primary oligodendrocytes protect neurons in culture from Hb toxicity via Hp release; (2) animals made hypohaptoglobinemic with repetitive Hb administration, before ICH, experience more extensive brain damage; (3) mice genetically engineered to overexpress Hp are less susceptible to ICH injury; and (4) Hp-deficient mice are more vulnerable to ICH injury. 20 In the context of therapeutic relevance, we have determined that pharmacological intervention with sulforaphane, a naturally occurring agent that acts as NF-E2-related factor-2 (Nrf2) transcription factor activator, increases Hp in blood plasma and brain, 20 and notably reduces brain damage in animal models of ICH. 24 In humans, the Hp gene exists in 2 major allelic forms designated as Hp1 and Hp2. Hp2 is produced via intragenic duplication of a 1.7-kb DNA fragment of Hp1 gene. Consequently, 3 major Hp genotypes are formed, Hp1-1, Hp1-2, and Hp2-2. 23 Hp2-2, the largest of the 3 Hp genotypes, has the lowest Hb-binding activity (Hp1-1ϾHp1-2ϾHp2-2) and, because of its size, represents potentially less bioavailable moieties. This may lead to a more defective Hb clearing system. 23 Interestingly, according to epidemiological studies, patients carrying the Hp2-2 genotype demonstrate more severe vasospasm after subarachnoid hemorrhage, more positive association with idiopathic seizures (and possibly posttraumatic epilepsy), and higher incidence of carotid atherosclerosis in diabetic patients. 23, [25] [26] The relevance of Hp genotype as a factor modifying the outcome after ICH has not been studied to date. During intracerebral hemorrhage (ICH), blood is released into the brain matter. Erythrocytes (red blood cells) are cleared from the parenchyma by microglia/macrophages through cell-surface scavenger receptor CD36-mediated phagocytosis. Timely clearance of the extravasated red blood cells and irreversibly injured cells prevents them from undergoing lyses and subsequent spillage of toxic contents into the brain parenchyma. In the case of hemolysis (what unavoidably occurs after ICH), hemoglobin (Hb) needs to be removed quickly from the extracellular space to avoid its cytotoxic effects. Haptoglobin (Hp), a protein arriving to the brain from blood and synthesized locally by oligodendroglia, tightly binds Hb, forming less toxic Hb-Hp complexes that are endocytosed by microglia/ macrophages through scavenger receptor CD163. The toxic extracellular free heme generated from Hb can be neutralized by binding to hemopexin (Hx). The heme-Hx complexes are subsequently removed by phagocytes via CD91 scavenger receptor-mediated endocytosis. In phagocyte, heme is metabolized by heme oxygenase (HO; primarily, HO-1) to biliverdin, carbon monoxide (CO), and prooxidative iron. To prevent oxidative cell damage, iron is sequestrated within phagocyte by iron-binding proteins such as hemosiderin or ferritin. Excessive production of iron may saturate storing capacity of hemosiderin, leading to oxidative injury from the free irons. CD36 is expressed under control of peroxisome proliferator-activated receptor-gamma (PPAR␥) and Hp expression is increased with NF-E2-related factor-2 (Nrf2). Both Nrf2 and PPAR␥ increase expression of antioxidant proteins (eg, catalase or superoxide dismutase). Thus, activation of these transcription factors may represent new targets for ICH treatment.
It could also be relevant for this review to indicate that in addition to the Hp-Hb/CD163 scavenging system, an independent system exists to help remove Hb breakdown products, heme, and iron. 27 Hemopexin (Hx) is a blood plasma glycoprotein synthesized primarily by hepatocytes. Hx has been shown to bind to heme with a high affinity and forms stable Hx-heme complexes. 2, 27 The heme-Hx complexes are readily endocytosed by macrophages expressing CD91 (␣ 2 -macroglobulin receptor, also known as low-density lipoprotein receptor-related protein-1). Although under physiological conditions CD91 plays a role in recycling iron in response to extravascular hemolysis in hematoma-affected tissue, the Hx-heme/CD91 system may facilitate removal of prooxidative heme by microglia/macrophages. 27 Recent studies 28 and ongoing research in this laboratory support this notion and suggest that Hx-deficient mice experience augmented ICH injury. More studies of the role of Hx in ICH are warranted.
Heme Oxygenase in ICH
Phagocytosis of intact erythrocytes, as well endocytosis of Hb and heme by macrophages/microglia, are instrumental for removing the pro-oxidative heme from the extracellular space of brain parenchyma. Phagocytic cells involved in this process express heme oxygenase (HO), a rate-limiting enzyme involved in heme catabolism that converts heme to biliverdin, carbon monoxide, and iron (FeII). 29, 30 There are 2 isoenzymes of HO; HO1 (also called HSP32) is an inducible form and HO2 is constitutively expressed. 29, 30 Whereas HO2 is moderately abundant in most cell types, including neurons, 29 HO1 expression after ICH is primarily induced in endothelial cells and microglia/macrophages. 29 Based on studies using genetically engineered mice, it was determined that HO2-null mice are more susceptible, 29 whereas HO1-null mice are more resistant 30 to ICH-mediated damage, as compared to wild-type mice. The improved outcome in the HO1-null mice after ICH is a surprise, because HO1 deficiency in many other brain injury models including ischemic stroke are associated with augmented brain damage. One potential explanation for such discrepancy is that HO1 deficiency could reduce the excessive liberation of free iron from erythrocytes in hematoma (feature that is unique to ICH) and consequently limit the iron-mediated oxidative stress. Although this scenario may provide logistics for reduced ICH injury in HO1-deficient mice, the presence of increased levels of Hp and Hx in HO1-deficiency animals 31 needs to be acknowledged, because these factors may contribute to cytoprotection independently of HO-1. Additional limitation regarding interpretation of the data on HO1-null mice susceptibility to ICH injury is that the outcome was characterized only up to 3 days and it did not address the role HO1 could play at later stages when a majority of hemolysis and clean-up takes place. This timing issue is of particular importance because HO1 deficiency makes phagocytic cells, the main executors of brain cleanup process, more prone to self-injury on processing of engulfed heme-containing red blood cell. 31 After ICH in mice, the clean-up process may last 3 to 4 weeks. 17 Another intriguing finding is that a robust HO1 upregulation in ICH-affected brain in response to treatment with sulforaphane coincides with a significant reduction of brain damage. 24 Sulforaphane promotes HO1 expression via Nrf2 through antioxidant response element. Interestingly, porphyrin derivatives that can be used to inhibit HO1, in contrast to sulforaphane, showed reduced ICH damage. 2, 32 Thus, more studies are required to clarify the role of HO1 in ICH.
Oxidative Stress and ICH Injury
As indicated, oxidative stress appears to play a prominent role in ICH pathogenesis. Direct evidence for the causal relationship between free radicals and ICH injury was by demonstrating the efficacy of antioxidants as therapeutic agents. Specifically, the free radical scavengers, such as dimethylthiourea, ␣-phenyl-N-tert-butyl nitrone, NXY-059 (a sulfonyl derivative of ␣-phenyl-N-tert-butyl nitrone) or deferoxamine, a drug chelating pro-oxidative iron, significantly reduced brain injury in animal models of ICH. 7, 19, 33, 34 In agreement with these pharmacological experiments, mice with generically deleted NADPH oxidase, a key enzyme involved in generating reactive oxygen species, showed reduced damage after ICH. 13 It recently has been demonstrated that estrogen reduces ferrous iron toxicity in vivo and in vitro, indicating that gender difference in susceptibility to ICH may, in part, be associated with differences in handling iron toxicity. 35 Although preclinical evidence exists for efficacy of therapy based on free radical neutralization, clinical trial with NXY-059 was surprisingly disappointing. NXY-059 was not only ineffective in ischemic stroke but also not beneficial in ICH patients. 36 The reason for these negative outcomes is unclear; however, factors such as pharmacokinetics of the drug (no blood-brain barrier permeability) and inability to stoichiometrically neutralize high levels of free radicals could likely contribute to these neutral results.
Deferoxamine and Iron Detoxification
Deferoxamine is another antioxidant currently in the early promising stages of clinical trial. 34 As indicated, toxicity of free iron originated from extravascular hemolysis, and HO-mediated catabolism is well-documented. 3 Iron (II), by reacting with H 2 O 2 generates hydroxyl radicals and deferoxamine, by forming stable complexes with iron prevents its engagement in oxidative reactions. One caveat exists that deferoxamine may act not only through preventing ironmediated pro-oxidative catalyzes but also via inhibiting prolyl hydroxylase activity (enzyme using iron as cofactor), which leads to HIF1␣ availability, a pathway with neuroprotective effect. Regardless of its mechanism, preclinical studies in a rat and pig ICH model showed promise for deferoxamine as therapy. 33, 37 Recently, a phase I study assessing the feasibility, safety, and maximum tolerated dose of deferoxamine in ICH patients was successfully completed (Magdy Selin, personal communication).
Role of Nrf2 in Oxidative Damage
In addition to increased free radical generation, damage to brain tissue may result from the impairment of the endogenous antioxidative enzyme system in response to ICH. Hua et al 38 reported a significant reduction in the levels of manga- 39 To activate Nrf2 in animals after ICH, we again utilized a naturally occurring organosulfur compound, sulforaphane. As expected, treatment with sulforaphane effectively increased the expression of Nrf2-regulated antioxidant genes, including catalase, superoxide dismutase, and glutathione-Stransferase, in brain tissue after ICH. 24 Notably, this expression of antioxidants corresponded to reduced oxidative damage to proteins and lipids within the ICH-affected brain and, importantly, with less severe neurological deficits. 24 To produce ultimate evidence for the beneficial involvement of Nrf2 in ICH pathogenesis, we established that mice deficient in Nrf2 (knockout) displayed more severe neurological deficit when subjected to ICH, implying that Nrf2 plays critical safeguard function in defending brain against oxidative stress associated with ICH pathogenesis. 24 Cytoprotective Effect of Peroxisome Proliferator-Activated Receptor-␥ Peroxisome proliferator-activated receptor-␥ (PPAR␥) is a ligand-dependent transcription factor that regulates target gene expression by binding to conserved DNA sequences termed peroxisome-proliferator response elements as heterodimers with another nuclear receptor, the retinoic acid receptor. 40 In addition to a well-characterized regulation of expression of genes involved in lipid and glucose metabolism and energy storage, activation of PPAR␥ induces expression of antioxidant catalase and copper/zinc superoxide dismutase, two ubiquitous enzymes capable of alleviating oxidative stress by decomposing hyperactive H 2 O 2 into molecular oxygen and water molecules, and dismutation of superoxide into oxygen and H 2 O 2 , respectively. 17, 41 The ligands for PPAR␥ include fatty acids, nonsteroidal anti-inflammatory drugs, 15Deoxy-⌬ 12,14 -Prostaglandin J 2 (15D-PGJ 2 , a reactive membrane lipid metabolite and downstream product of prostaglandin D 2 , proposed to act as a physiological PPAR ␥ agonist), and the thiazolidinediones (specifically pioglitazone and rosiglitazone), a class of compounds commonly used to treat type 2 diabetes. 41 Using rat model of ICH based on intrastriatal autologous blood injection, we recently reported that intrahemorrhage injection of 15D-PGJ 2 activates PPAR␥ in the brain tissue and increases expression of catalase in ICH-affected brain, primarily in neurons and microglia. 17, 41 These biochemical responses were associated with decreased neuronal death, as demonstrated by the incidence of DNA scission in neurons, and reduced neurological dysfunction. 41 These findings are consistent with studies demonstrating that PPAR␥ plays an important role in protecting neurons and other brain cells from injury caused by oxidative stress and ischemia. 17, 42 Inflammation, Blood Toxicity, and Hematoma
Removal as Target for ICH Treatment
The brain-resident phagocytes, microglia, are highly abundant (10%-15% of total glial cells) in brain and become readily activated within minutes after ICH. 7, 11, 43 The activated microglia release proinflammatory cytokines and chemotactic factors, which help to recruit hemotogeneous inflammatory cells to the ICH injury sites. This is characterized first by the transient (18 hours-4 days) infiltration of neutrophils and then a long-term (1 day-months) presence of hematogenous macrophages. [7] [8] 43 The inflammatory signaling involves a coordinated effort of different molecules and cell types and is largely coordinated by a ubiquitous transcription factor, nuclear factor kappa-B (NF-B). 9, 44 The gene targets of NF-B include various adhesion molecules (including these involved in immune cells extravasation, eg, intercellular adhesion molecule-1), cytokines, and chemokines (involved in proinflammatory signaling and NF-B activation, eg, IL-1␤ and tumor necrosis factor-␣), metalloproteinases (eg, matrix metalloproteinase-9), immune receptors, acute phase proteins, cell surface receptors, and inflammatory enzymes (eg, inducible nitric oxide synthase, COX-2, and PLA2). It is important to mention that free radicals act as important signaling molecules in NF-B activation. This property of NF-B may, in part, explain how oxidative stress could enhance inflammation after ICH. Experimental studies demonstrate that NF-B is activated in ICH-affected hemisphere as early as 15 minutes after the onset of ICH, reaches maximum between 1 and 3 days, and remains elevated for weeks. 44 It is pertinent to indicate that NF-B target genes including IL-1␤, tumor necrosis factor-␣, and matrix metalloproteinase-9 are involved in ICH-mediated brain injury. 11, [45] [46] [47] [48] Albeit some inflammatory responses generated by microglia/macrophages after ICH may aggravate brain injury, microglia/macrophages-mediated phagocytosis is instrumental in conducting brain clean-up, the process that must occur to allow for tissue repair and functional recovery. 17 A fast and efficient removal of apoptotic, dislocated (eg, extravascular erythrocytes), and damaged cells before the discharge of injurious and proinflammatory cell contents (damageassociated molecular patterns) occurs and may help to reduce secondary damage.
Microglia and macrophages express various cell surface receptors, including scavenger receptors (eg, CD91, scavenger receptor-A, MARCO, scavenger receptor-BI, and CD36) that assist in phagocytosis/endocytosis-mediated removal of cellular debris after tissue injury, including brain injury after ICH. 49 One specific study evaluated CD36, a class II scavenger receptor that is transcriptionally regulated by PPAR␥. This study used in vitro and in vivo models and demonstrated that: (1) microglia/macrophages utilize CD36 to promote phagocytosis of red blood cell; and (2) treating animals with PPAR␥ agonists (eg, rosiglitazone, pioglitazone, or 15D-PGJ2), which increased CD36 expression, results in faster hematoma resolu-tion and improved functional recovery after ICH. 17 The most intriguing observation in this study was that the activation of phagocytosis with PPAR␥ agonist in both in vitro and in vivo experiments was associated with the reduced proinflammatory responses (eg, reduced IL-1␤, tumor necrosis factor-␣, and matrix metalloproteinase-9 mRNA expression). 17 Because one of the mechanisms of PPAR␥ is to transrepress DNA binding of NF-B, it is likely that the anti-inflammatory phenotype of PPAR␥ is mediated through inhibition of NF-B. 41 Based on these promising preclinical data with PPAR␥ agonists, a randomized clinical trial evaluating safety of pioglitazone for hematoma resolution in ICH was initiated in 2009 (http://clinicaltrials.gov).
In conclusion, existing experimental data suggest that interventions interfering with proinflammatory and prooxidative blood toxicity through either direct neutralization of Hb, heme, and iron or improvement of its removal from extracellular space by phagocytes (eg, through modulation of PPAR␥, NF-B, and Nrf2) represent potential therapeutic targets for ICH (Figure 2 ).
Sources of Funding
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